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studies should now look at the associa-
tion of MMP-10 (and other proteases and 
their inhibitors) with the infl ammatory 
component of atherosclerosis as meas-
ured by fluorodeoxyglucose positron 
emission tomography imaging, and with 
stable and unstable atherosclerotic lesions 
as identifi ed by nuclear magnetic reso-
nance or other advanced imaging meth-
ods. Cutting-edge methods now allow 
MMP activity to be measured  in vivo , 
and these are being explored in experi-
mental research, 13 which off ers tremen-
dous opportunities for investigators 
interested in this fascinating and promis-
ing research issue. Finally, the predictive 
power of MMPs for clinical events needs 
to be addressed in well-powered cohort 
studies and, ultimately, in clinical trials. 
MMP activity can be reduced by sele-
ctive or unselective MMP inhibitors, by 
control of the infl ammatory component 
of atherosclerosis, or by a combination of 
these interventions. Even though no clear 
(experimental) treatment strategy target-
ing MMPs has emerged until now, dys-
regulated metalloproteinase activity 
remains a valid research goal for therapy 
of unstable, risky atherosclerotic lesions, 9 
and clinicians should stay tuned in to 
this translational territory of cardiovas-
cular medicine. 
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 Acute kidney injury (AKI) is still a major 
clinical problem. It is diagnosed in 1 % of 
hospital admissions, and up to 7 % of 
hospitalized patients develop AKI. 
Twenty-fi ve percent of patients in inten-
sive care units develop AKI, and 20 % of 
them will need renal replacement 
therapy. Dialysis is the only treatment 
approved by the US Food and Drug 
Administration for AKI, and the mortal-
ity of AKI is as high as 80 % in intensive 
care unit patients. AKI remains an inde-
pendent risk factor for mortality and 
morbidity, especially in patients under-
going thoracoabdominal aortic surgery, 
cardiac surgery, or bone marrow trans-
plantation, in those receiving ampho-
tericin B or cisplatin therapies, and in 
patients with liver cirrhosis. 1 
 Current AKI diagnosing and staging 
criteria are entirely based on an increase 
in serum creatinine or a decrease in 
urine output. Serum creatinine changes 
are unacceptably insensitive markers of 
AKI, as creatinine levels increase in 
blood only after marked reduction of 
glomerular fi ltration, hence when kidney 
injury has already progressed. 1 In addi-
tion, urine output is aff ected by the use 
of diuretics or by prerenal azotemia. 
Published animal studies clearly demon-
strated that, to be eff ective, treatment of 
AKI should be started very early aft er the 
insult and well before the rise of serum 
creatinine. Thus, sensitive biologic 
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 markers of renal tubular injury in AKI 
are strongly needed. Recently, urinary 
biomarkers such as interleukin-18, 
kidney injury molecule-1 (KIM-1), and 
neutrophil gelatinase-associated lipo-
calin (NGAL) have been used for the 
early diagnosis of AKI, although with no 
defi nitive results. 
 Hu  et al. 2 (this issue) investigated the 
role of Klotho as a novel biomarker and 
therapeutic target in a model of AKI 
induced in rats by ischemia – reperfusion 
injury. Th e  klotho gene, identifi ed as an 
 ‘ aging suppressor ’ gene in mice, encodes 
for a single-pass transmembrane protein 
and is expressed primarily in renal 
tubules. 3 The extracellular domain of 
Klotho is clipped by the membrane-
anchored proteases ADAM10 and 
ADAM17 to generate a secreted form. 
Th e two forms of Klotho protein exert 
distinct functions. Membrane Klotho 
functions as an obligate co-receptor for 
FGF23, a bone-derived hormone that 
induces phosphate excretion into urine. 
Secreted Klotho functions as a humoral 
factor that regulates activity of multiple 
glycoproteins on the cell surface, includ-
ing ion channels and growth factor 
receptors such as insulin / insulin-like 
growth factor-1 (insulin /  IGF-1) 
 receptors, possibly through its sialidase 
activity ( Figure 1b ). Several studies, 
mainly in the context of aging, have docu-
mented that Klotho also possesses other 
functions, such as antiapoptotic and anti-
oxidant eff ects. 4 
 Hu  et al. 2 found reduced Klotho in kid-
neys, urine, and blood of AKI rats, which 
returned to normal upon recovery. 2 Th e 
fi nding of renal Klotho reduction in AKI 
is not completely new, as a previous study 
showed decreased renal Klotho mRNA 
and protein in rats at 1 day aft er ischemia –
 reperfusion. 5 Th e interesting new fi nding 
of the study by Hu  et al. 2 is the rapid 
Klotho decrease in the plasma and in the 
urine, detectable as early as at 3  h aft er 
injury. Klotho changes occurred earlier 
than changes in serum creatinine (24  h) 
and even changes in NGAL (5  h), suggest-
ing that Klotho could be a novel biomar-
ker for AKI diagnosis. Th e authors also 
found lower Klotho levels in the urine of 
AKI patients as compared with healthy 
subjects; however, they did not evaluate 
the time course of Klotho decrease in 
relation to serum creatinine and NGAL 
levels, which is mandatory to establish 
the diagnostic potential of the marker. 
Another relevant issue not addressed by 
Hu  et al. 2 is the specificity of Klotho 
decrease for AKI, as the ideal biomarker 
 Figure 1  |  Effect of Klotho in AKI. ( a ) Mechanisms and inflammatory mediators of ischemia – reperfusion-induced acute kidney injury (AKI). 
( b ) Potential protective effects of Klotho against AKI, in the endothelium and in tubules. CAT-1, catalase-1; Hsp70, heat shock protein 70; 
mK, membrane Klotho; NO, nitric oxide; ROS, reactive oxygen species; sK, soluble Klotho; SOD2, superoxide dismutase-2. 
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must be specifi c to the disease state being 
examined. Th ere are very few studies on 
changes in renal, serum, and urine levels 
of Klotho in experimental animals and 
humans. Rats with streptozotocin-
induced diabetes, 6 or doxorubicin hydro-
chloride-induced nephropathy 7 or 
uremia, 8 showed reduced renal expres-
sion of Klotho protein. Th e reduction in 
renal Klotho expression observed in rats 
with doxorubicin hydrochloride-induced 
nephropathy was mitigated by treatment 
with erythropoietin, indicating that 
Klotho expression can be pharmacologi-
cally modulated. 7 Finally, in healthy sub-
jects, serum Klotho levels were very 
variable and were inversely correlated to 
serum creatinine and to the age of sub-
jects. 9 Th us, further clinical studies are 
required to establish the timing of urine 
and possibly serum Klotho changes in 
AKI and their specifi city. 
 Very interestingly, Hu  et al. 2 also docu-
mented that soluble Klotho was eff ective 
in attenuating AKI when administered 
30  min after the ischemic insult. The 
earlier that Klotho was administered, the 
better was the renal protection against 
AKI. Indeed, Klotho given 60  min aft er 
ischemia, although still eff ective, showed 
a less efficient renoprotection. If these 
results are translated into the clinical 
setting, then Klotho would potentially 
function more effi  ciently as a preventive 
than as a repairing agent. 
 In ischemic AKI, the initial insult 
results in morphologic and functional 
changes of vascular endothelial cells and 
tubular epithelium ( Figure 1a ). Impair-
ment of nitric oxide-mediated vasodila-
tation and release of vasoconstrictors 
cause contraction of the vessel wall. 
Activated endothelial cells express high 
levels of surface adhesion molecules and 
produce cytokines and chemokines 
capable of attracting infl ammatory leu-
kocytes in the interstitium, where they 
release oxygen radicals, proteases, and 
cytokines. Such a cascade of events ends 
eventually in tubular-cell apoptosis and 
necrosis ( Figure 1a ). 
 Th e mechanism by which Klotho exerts 
its protective eff ect against AKI is not 
investigated in the paper by Hu  et al. 2 Th e 
authors hypothesized that Klotho may 
counteract AKI in tubular cells by 
 reducing the mitochondrial oxidative 
stress as well as by directly inhibiting the 
apoptosis ( Figure 1b ). If Klotho alleviates 
oxidative stress, it may protect tissues 
from ischemia and infl ammation asso-
ciated with AKI. That Klotho may 
induce resistance to oxidative stress is 
supported by published  in vitro and 
 in vivo studies. 4 Klotho activated FOXO 
transcription factors by blocking insulin /
 IGF-1-mediated FOXO phosphorylation 
 in vitro . Dephosphorylated FOXOs in 
turn upregulated the expression of anti-
oxidant enzymes such as catalase-1 and 
mitochondrial manganese superoxide 
dismutase (SOD2).  In vivo , Klotho-
 overexpressing transgenic mice have 
higher levels of the antioxidant enzyme 
superoxide dismutase (SOD) in muscle 
and less phosphorylated FOXO, which 
is associated with oxida tive stress. 
In a model of experimental immune-
mediated glomerulonephritis, increasing 
Klotho by genetic manipulation reduced 
mitochondrial DNA fragmentation, 
superoxide anion generation, lipid per-
oxidation, and apoptosis. 10 Whether such 
mechanisms could explain the protective 
eff ect of Klotho against AKI remains to 
be determined. 
 Other authors have suggested that 
Klotho may exert an antiapoptotic eff ect 
on tubular cells through upregulation of 
heat shock protein 70 (Hsp70) ( Figure 1b ), 
which stabilizes the antiapoptotic Bcl-2 
and Bcl-xL proteins. This was docu-
mented in a mouse experimental model 
of AKI in which adenoviral transfection 
with Klotho upregulated Hsp70 and 
reduced tubular apoptosis. 11 Finally, evi-
dence is also emerging that Klotho mod-
ulates nitric oxide (NO) synthesis. 4 
Endothelium-dependent vasodilatation 
in response to acetylcholine is attenu-
ated in aorta and arterioles from Klotho-
defi cient mice, indicating that Klotho 
deficiency causes a reduction of NO 
syn thesis in vascular endothelial cells. 
 In vivo , Klotho gene delivery using an 
adenoviral expression vector increased 
endothelium-dependent NO synthesis in 
a rat model of multiple atherogenic risk 
factors. Whether Klotho may ameliorate 
renal perfusion in AKI by preserving NO 
synthesis and activity remains to be 
determined. 
 In summary, Hu  et al. 2 document that 
AKI is a state of acute Klotho defi ciency, 
that reduction of Klotho in serum and 
urine occurs very rapidly aft er AKI, and 
that Klotho administration possesses a 
therapeutic potential, at least in ischemia-
induced AKI. Whether Klotho plays a role 
also in AKI induced by other causes, such 
as nephrotoxic agents or endotoxemia, is 
worth investigating. In addition, further 
studies are required to evaluate the sensi-
tivity and specifi city of Klotho changes in 
serum and urine for early diagnosis of 
clinical AKI. 
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